Drug Profile
Research programme: pulmonary hypertension therapeutics - Icagen/Omdana Theapeutics
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Icagen, Inc.; Omdana Therapeutics
- Class Antihypertensives; Small molecules
- Mechanism of Action RXFP1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary hypertension
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Pulmonary-hypertension in USA
- 16 Nov 2019 Pharmacodynamics data from a preclinical trial in Pulmonary hypertension presented at the American Heart Association Scientific Sessions (AHA-2019)
- 18 May 2018 Preclinical trials in Pulmonary hypertension in USA (unspecified route) before May 2018